Overview

PARP Inhibition for Gliomas (PI-4G or π4g)

Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Oklahoma
Collaborator:
GlaxoSmithKline
Treatments:
Niraparib